PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Health Care Poor Underserved. Author manuscript; available in PMC Sep 30, 2013.
Published in final edited form as:
PMCID: PMC3786672
NIHMSID: NIHMS490443
Hepatitis C Among Clients of Health Care for the Homeless Primary Care Clinics
Aaron J Strehlow, RN, PhD, FNP-BC, FNP-C, NPNP, Marjorie J. Robertson, PhD, Suzanne Zerger, PhD, Catherine Rongey, MD MSHS, Lisa Arangua, Ed Farrell, MD, Adele O’Sullivan, M.D., and Lillian Gelberg, MD, MSPH
Aaron J Strehlow, UCLA School of Nursing 1228 N La Cienega Blvd., #102 West Hollywood, CA 90069-2485 (310) 659-7761 Cell: 213-220-4176 ; astrehlo/at/ucla.edu;
Objectives
To describe the prevalence, distribution and risk factors for hepatitis C virus (HCV) infection among homeless adults using eight Health Care for the Homeless (HCH) clinics nationally.
Methods
Data were collected for 387 participants through blood draws, structured interviews, chart reviews.
Results
Overall prevalence of HCV-antibody positivity was 31.0%, including 70.0% among injection drug users and 15.5% among reported non-injectors. Much HCV infection was “hidden” as the majority (53.3%) of HCV-antibody positive participants was unaware of their status. Independent risk factors for HCV among the total sample included injection drug use, prison and tattoos; among injectors, risk factors included prison and ≥ 3 years of injection drug use; and among reported non-injectors, risk factors included tattoos and prison.
Conclusion
These HCH clinics serve high concentrations of HCV-infected injectors, making these and similar clinics priority intervention sites for aggressive screening, education, testing, and treatment for HCV and other blood-borne diseases.
Keywords: homeless, hepatitis C, Health Care for the Homeless, tattoos, injection drug use, prison, risk factors, primary care clinics, blood borne disease, infectious disease, sexual risk
Hepatitis C is a contagious liver disease caused by the HCV virus (HCV) that is transmitted by direct exposure to infectious blood, and it constitutes a serious public health problem worldwide. 1 The US prevalence of hepatitis C is estimated to be 1.6% (or 4.1 million). 2 Most of these [an estimated 1.3% (or 2.7 to 3.9 million)] have chronic HCV.1-2 Although HCV-related diseases have a slow progression among persons with chronic HCV, chronic HCV infection is the leading cause of cirrhosis and liver cancer. 1, 3-5 The prevalence of hepatitis C cirrhosis and its complications are expected to increase through 2020 in the US due to infections acquired between 1970 and 1990.6-7 A disproportionate burden of HCV in the US has been demonstrated for persons who have low family income or a prison history; who are non-Hispanic Black males, HIV-infected, or Vietnam veterans; or who were born between 1945 and 1964.2, 5
Recent US prevalence estimates cited above are based on a national household survey, the National Health and Nutrition Examination Survey (NHANES) from 1999 through 2002.2 The NHANES estimates are based on a national household sample that included non-institutionalized persons ages six and older.2 The NHANES did not include understudied populations such as homeless persons or prison inmates, both of which have relatively higher rates of HCV5, 8-9 and lower access to medical services where HCV might be diagnosed and treated. 1, 10 Higher rates of HCV have also been reported in US mental health treatment institutions. 11-12 Rates of newly acquired HCV infections appear to be declining 4, 13-14, although interpretation of this trend is complicated by the failure to include many injection drug users and other high-risk groups in the current surveillance systems. 1
Earlier studies of HCV in US homeless adults report HCV rates that range widely between 26.5% and 69.1%, 15-20 depending on each study’s demographic profile and sample source. Studies have been based on diverse sampling sites 9, 16, 18, 21 and on very specific homeless sub-populations such as youth, veterans in domiciliary care, HIV-infected persons, injectors, and persons with serious mental illness or co-occurring substance use with major mental disorders. 15-17, 20 One study reported retrospective test results (i.e., based on self-reported results of prior HCV tests) with questionable validity. 17 Several studies found severity of homelessness to be an independent factor for HCV including Hall and colleagues who reported homelessness to be an independent risk factor for HCV among urban poor in San Francisco.9, 15
In the past decade, the National Institutes of Health (NIH) and the Centers for Disease Control (CDC) have outlined a national agenda for HCV research that recommends continued epidemiological monitoring and studies on the specific modes of transmission among racial and ethnic minority persons, low socioeconomic groups, and injection and intranasal drug users.22-23The NIH and the CDC have emphasized that early detection and treatment, along with educational efforts for high-risk and infected persons, are crucial elements of the national health agenda for preventing the spread and consequences of HCV. The Institute of Medicine’s (IOM) 2010 report on a national strategy for prevention and control of hepatitis B and C reported that reducing the rates of illness and death associated with hepatitis C will require improved identification of at-risk people and improved access to medical care.1
The NIH, CDC, and IOM Reports are pertinent to healthcare providers who serve homeless clients due to the high prevalence of HCV among homeless persons who generally experience impaired health status and whose lives are already complicated by social demands. 1, 22-23
In contrast to previous studies, the present study investigated the seroprevalence, distribution, and risk factors for HCV in a broader cross section of the homeless population; that is, homeless adults that attended eight Health Care for the Homeless Program (HCH) primary care clinics. The HCH is funded by the Bureau of Primary Health Care of the US Health Resources and Services Administration. The federally funded HCH grantees serve about 700,000 persons yearly. This study analyzed the epidemiology, distribution, and risk factors for HCV among 387 homeless clients systematically sampled from eight of 185 HCH clinics nationally. The results of this multi-site study will inform policy makers and healthcare providers about the extent and risk factors for HCV among homeless adult clients of selected HCH clinics. In doing so, the paper will describe HCV prevalence and risk factors for exposure among a high-risk population. Findings will support the ongoing national agenda for preventing the spread and consequences of HCV to homeless persons and the broader community.
Design
For this community-based study, the HCV Task Force of the Health Care for the Homeless Clinicians’ Network (HCHCN, a membership group of the National Health Care for the Homeless Council), which included HCH clinicians and researchers, worked collaboratively to design and oversee this study from its inception, including development of the fieldwork protocol and data collection instruments. Lead clinicians from the HCH Hepatitis C Task Force volunteered their clinics as study sites and agreed to lead their clinic’s onsite data collection. Additional clinics were recruited to balance geographic distribution. A $500 incentive was provided to each participating clinic to partially offset staff time used for data collection.
Eight clinics were chosen from geographically diverse urban settings. Although the clinics were not randomly selected, they were selected from diverse regions of the US including Los Angeles, CA; Phoenix, AZ; Denver, CO; Albuquerque, NM; Des Moines, IA; Milwaukee, WI; Birmingham, AL and Providence, RI.
Study protocols were piloted at three sites. Researchers and HCH project staff worked with clinical teams at each clinic to tailor the standard research protocol to each site. Then each clinical team, which would be collecting all data for the study at their respective sites, also piloted data collection and fieldwork protocols at their own sites. During the data collection period, the HCH Project Director and the researchers were available on-call throughout the data collection process to address emerging issues and concerns. Training in laboratory procedures was similarly carried out between the Project Director, individual site staffs, and the independent laboratory coordinator. The lab coordinator met with individual sites to discuss the lab protocol including blood testing, storage and mailing procedures. All blood was tested at a centralized laboratory.
Sampling, screening, and recruitment
The recruitment goal was fifty homeless adult clients randomly sampled from each of the eight study clinics for a total sample size of 400. Clients were sampled systematically with a random start. Lead clinicians continued recruitment over a number of days until a sample size of 50 clients was completed for each clinic.
At the beginning of the clinic day, an intake staff person systematically sampled potential subjects from the appointment list or intake roster, for example, by sampling every fifth client after a random start. In turn, each of these clients was screened for eligibility for the study based on two criteria: age (18 and older) and meeting the federal definition of literal homelessness. “Literal homelessness” was based on one question about the place where the client had spent the previous night. Eligible clients were invited to complete an interview and blood draw to test for HCV and hepatitis B (HBV) infections. The clinician then obtained written informed consent to participate in the study. A separate consent form authorized subsequent access to each client’s medical records to determine whether they returned for their respective test results.
Each client completed a 20-minute face-to-face interview with the lead clinician followed by tailored pre-test counseling for HBV and HCV and a blood draw. Each client received an incentive of $10 cash or a $10-cash equivalent for completion of all three. Clients were then scheduled for an appointment in the same clinic about two weeks later to obtain the results of their blood tests.
Blood specimens were sent to and tested by an independent central laboratory. Only HCV antibody results were analyzed here. To assess for HCV, blood specimens were analyzed for the HCV antibody and alanine aminotransferase (ALT). Based on the CDC suggested protocol, confirmation of HCV antibody positivity was conducted using the recombinant immunoblot assay (RIBA) test for cases in which the signal-to-cutoff ratio was less than 3.8 on the initial anti-HCV antibody EIA test.24
Individual lab results were faxed back to respective clinics and affixed to each client’s medical chart by clinic staff. Depending on their HCV test results, returning clients received tailored post-test counseling and usual treatment according to local clinic protocols. The HCH Task Force provided written pre- and post-test counseling guidelines as a resource for the clinics.
Data Collection
The structured interview included questions about sociodemographic characteristics and background; homelessness history; detailed medical, psychiatric, and prison history; HCV-specific knowledge and prior testing; and recent alcohol use. Questions also included potential risk behaviors for HCV transmission including lifetime drug use [e.g., drugs used, modes of use (i.e., injection, intranasal, or smoked), and sharing of injection and other drug-use equipment]; tattoos; transfusions before 1990; and sexual risk behaviors (that included number of lifetime sex partners, trading sex for cash or drugs, and lifetime anal sex). The instrument was adapted from a prior study of homeless and other indigent adults. Additional items were developed by the HCHCN HCV Task Force to address specific concerns of clinical staff.
The completion rates varied by site from 92% to 100%. Overall, 396 clients completed interviews, and among these, 387 had blood draws for an overall completion rate of 97.7%. In six clinics, lead clinicians reviewed medical records for 300 participants to determine whether each one returned for results. Among these, records indicated that 186 (62%) participants returned to the clinic during their respective 30-day follow-up periods.
The University of California Los Angeles (UCLA) Institutional Review Board (IRB) served as the multiple project assurance agency that approved the study. The study was also approved by the Federal Office of Management and Budget and individual clinic IRBs. Prior to onset of data collection, all research and clinic personnel involved in the study completed an online UCLA IRB course in the protection of human subjects.
Data analysis
Data from the eight clinics were merged into an aggregated dataset. Data analysis was performed using SAS 9.0. Categorical variables were created for age (45 < and 45+), number of lifetime sexual partners (15< or 15+), chronic homelessness (one year or more accumulated since age 18 versus less than one year), tattoos, and years of injection drug use. Differences between sites were analyzed using Chi Square tests. At the bivariate level, associations between categorical variables and HCV infection were examined with odds ratios (OR) and 95% confidence intervals (CI).
Three logistic regression models were developed to identify variables independently associated with HCV infection for the total sample and for two mutually exclusive groups: i.e., those who reported injection of any illicit drugs in their lifetimes, and those who reported none. Each model initially included all variables that were at least marginally associated with HCV status in the bivariate analysis (p≤0.10). Each model also controlled for age as a continuous variable, biological sex and race. Variables were entered into stepwise backward logistic regression models to create a core model, and then they were confirmed using stepwise forward analysis. Variables in each core model were examined and corrected for multicollinearity, defined as correlations greater than 0.5 and a variance inflation factor greater than or equal to four. Model fit was judged by the comparison of the −2 log-likelihood of model improvement and Wald statistics of the beta coefficients.
Sample Overview
The majority of the sample was male, non-white, and high school graduates with a median age of 44 (Table 1.) Few self-identified as gay or bisexual (5.9%). Most experienced chronic homelessness (i.e., one year or longer cumulatively as an adult), and half (51.7%) were homeless for two years or longer. Sixteen per cent of the sample (21% of men, not shown) were US military veterans. During the 30 days prior to the interview, about half the sample had used alcohol at least once, and about one-third of the sample reported hazardous drinking ( i.e., they drank four or more drinks on at least one of those days).
Table 1
Table 1
Distribution of hepatitis C antibody for the total sample and by site stratified by Injection Drug Use History (N=387).
Regarding potential risk factors for HCV, more than one-third of the sample had ever been in prison. Two-fifths of the sample had at least one tattoo. Fourteen percent reported a transfusion of blood or blood products before 1990. Regarding sexual history, about half reported more than 15 sexual partners, and about one fifth had ever been paid for sex or been given drugs for sex. More than one-third (38.5%) of women and 3.3% of men reported lifetime anal sex.
Lifetime drug use was highly prevalent, with three-quarters reporting illicit drug use at least once. More than half (54.8%) of the sample had ever snorted cocaine. Many (28.4%) had ever injected illicit drugs, including heroin, cocaine and speed, and half of these had injected drugs during the previous 12 months.
HCV seroprevalence and distribution
Overall, 31% of the sample was HCV-antibody positive. The majority of clients who tested HCV antibody positive (53.3%) were unaware of their status. In all sites, HCV was significantly associated with rates of IDU (i.e., HCV ranged from 55.6% to 81.8% among injectors in eight study sites). Injectors accounted for the great majority (nearly two-thirds) of all HCV-positive clients in all clinics studied. HCV prevalence varied only marginally by site (p < .086) (Table 1), largely a function of the proportion of injection drug users.
Bivariate associations with HCV for the total sample
In bivariate analysis of the total sample, HCV rates were significantly higher among men, older persons, and adults with more education (Table 1). HCV was also higher among adults with time in prison, tattoos, recent hazardous drinking, 15 or more lifetime sexual partners, and a history of trading drugs for sex. HCV rates were significantly lower in African Americans. High risk lifetime sexual practices such as anal sex or having been paid cash for sex were not significantly associated with HCV. Drug use history was associated with HCV antibody positivity including lifetime illicit drug use, intranasal use of cocaine, and injection drug use. We conducted a subgroup analysis by injection history.
Bivariate associations with HCV for injectors
HCV prevalence among lifetime injection drug users was 70.0%. The injector subgroup was mostly male, white, and high school graduates, with a median age of 44 (Table 3). The majority had been in prison and had tattoos. The median time using injection drugs was 3.5 years, and HCV rates rose rapidly as a function of time injecting (i.e., HCV was 45.5% at less than one year, 60.0% at 1 to <3 years, and 81.4% at ≥ 3 years). More than 70% had been chronically homeless ( ≥ 1 year). Among injectors, HCV-antibody positivity was significantly higher among participants who were age 45 or older, were former prison inmates, had injected drugs for three years or longer, or had ever injected cocaine or injected heroin. Hepatitis C rates were only marginally higher for males compared to females, for Hispanics compared to non-Hispanic Whites, and for participants reporting fifteen or more lifetime sexual partners.
Table 3
Table 3
Prevalence of hepatitis C antibody (HCV+) among homeless adult clients of eight HCH clinics by background characteristics and potential risk behaviors, stratified by history of injection drug use (N=387).
Bivariate associations with HCV for non-injectors
In the subgroup that reported no history of injection drug use, 15.5% were HCV-antibody positive. The non-injector subgroup was predominantly male, non-white, and high school graduates with a median age of 45 (Table 3). One-third had ever been in prison or had tattoos. Two-thirds of the non-injector subset had used illicit drugs. Two-fifths had more than 15 lifetime sexual partners. In the non-injector subgroup, HCV positivity was significantly higher among men, Native Americans compared to non-Hispanic Whites, participants with tattoos, former prison inmates and those who had ever been paid for sex. HCV rates were only marginally higher among more educated participants and those never given drugs for sex.
Multivariate associations with HCV for the total sample
Logistic regression analysis was used to identify significant risk factors for HCV antibody positivity in the total sample and then for the injector and non-injector subgroups, controlling for age (as a continuous variable), biological sex and white vs. non-white race (Table 4.) In the total sample, lifetime injection drug use, prison history, and having tattoos were significant independent predictors for HCV-antibody positivity. That is, injectors had 12.2 times greater odds of testing positive for HCV compared with the rest of the total sample. Participants with a prison history or tattoos had respectively 2.9 and 2.7 times greater odds of testing positive for HCV compared with the rest of the total sample.
Table 4
Table 4
Factors independently associated with hepatitis C antibody positivity (HCV+) among homeless adult clients of eight HCH Clinics for the total sample and stratified by injection history.
Multivariate associations with HCV for the injector sub-sample
Among the injector subsample, prison history and three or more years of injection drug use were significant independent predictors of HCV-antibody positivity. That is, among injectors, those with prison history or at least three years of injection drug use had respectively 3.7 and 3.3 times greater odds of testing positive for HCV compared to other injectors.
Multivariate associations with HCV for the non-injector subsample
Among the non-injector subsample, having tattoos and prison history were significant independent predictors of HCV-antibody positivity. That is, among non-injectors, those with one or more tattoos or time in prison had respectively 4.4 and 2.2 times greater odds of testing positive for HCV compared to other non-injectors.
HCV testing history, knowledge, and hidden infection
About 41.7% of the sample reported prior HCV testing. However, more than half (53.4%) of participants who actually tested HCV positive did not know they were currently HCV positive. While a great majority of the sample knew they could get infected with HCV from using a “dirty” or contaminated needle or syringe (90.2%), only about one-third knew that they could not get infected with HCV from contaminated food (35.2%) or that there was no vaccination against HCV (30.3%) (not shown).
This study reports the prevalence, distribution, and risk factors for HCV infection among homeless clients from eight Health Care for the Homeless Program primary care clinics nationally. The prevalence of HCV infection overall (31.0%), was in the lower range of estimates and similar to the rates found in two previous studies of homeless adults. 9, 17 HCV prevalence rates varied only marginally by site and were largely a function of the percentage of injection drug users.
Overall, and in each of the clinics (ranging from 18.0%-47.9%), HCV rates were high relative to the estimated HCV rate for the US general population (1.6%). Unfortunately, the US estimate is based on the general population ages six and older, which deflates the nation; 144(10):705-14nal HCV rate and which exaggerates the difference between rates of HCV between homeless adults and the general population.
Total sample
Generally, the burden of HCV fell more heavily on males, older clients, and clients with time in prison, tattoos, recent hazardous drinking, 15 or more sexual partners, and a history of trading drugs for sex. In contrast to the general population, HCV prevalence was significantly lower for non-Hispanic Blacks and clients with lower education. 2 In bivariate analysis, important drug-use correlates of HCV-antibody positivity were lifetime injection drug use (heroin, crack, and speed), lifetime illicit drug use, and intranasal use of cocaine. As reported here for the majority of HCV-positive homeless clients (53%), many high-risk populations in the US similarly lack knowledge about HCV including chronic HCV infection. 1
Consistent with the broader literature on HCV, the primary independent risk factor for HCV in this sample was injection of illicit drugs. More than one-quarter of the sample (28%) reported lifetime injection drug use compared to an estimated 2% in the US general adult population.2 Among homeless injectors, 70.0% tested HCV-antibody positive compared to 57.5% among injectors in the general adult population, ages 20 to 59.2 Rates for the eight clinics ranged from 55.6% to 81.8%. While injectors represented about one-quarter of the entire sample (28.4%), they accounted for nearly two-thirds (64.2%) of HCV-positive cases. Injectors were twelve times more likely than other clients to be HCV-positive. Overall, about one in five homeless adults in the sample (19.9%) was an injector who tested positive for HCV. Strikingly, HCV rates rose rapidly as a function of duration of injection drug use: HCV rates were 45.5% at less than one year, 60.0% from one up to three years, and 81.4% for three years or longer.
Homeless injectors
The HCV rates for homeless and general population adults are more similar with comparisons by similar ages and risk factor. Homeless adult injectors (ages 18 and older) had a higher rate of HCV (70.0% reported here) compared to adult injectors in the general population (ages 20-59), which is estimated at 57.5% based on the NHANES data.2 Nearly two-thirds of homeless adults who were HCV-positive reported histories of injection drug use, while by comparison, only about half of HCV-positive adults in the general population reported injection histories.2 The rate of HCV among injectors in our sample (70%) was higher than the rates among housed young injectors in Los Angeles (27%), but similar to the range of HCV rates found among longer-term injectors in other samples (65-90%).1
Homeless non-injectors
Reported non-injectors had significantly lower yet still noteworthy rates of HCV positivity (15.5%) compared to non-injectors in the general US population, which ranged from 0.7%-3.5%.2 Non-injectors accounted for more than one-third of the HCV-positive clients (35.8%). Homeless non-injectors had high HCV infection rates (15.5%) In multivariate analysis, ever getting a tattoo or having a prison history were independent risk factors for HCV-positivity. Among non-injectors, clients with any histories of prison or tattoos were respectively two and four times more likely to test HCV-positive.
Specific risk factors for HCV
Prison History
As reported in previous studies, prison exposure was a significant independent risk factor for HCV infection for the total sample and the injector and non-injector subgroups, even after controlling for sex, race and age. Strikingly, 38% of the sample reported time spent in prison, and about half these were HCV antibody positive (50.7%), a rate that is higher than the range found in incarcerated populations in the US (12-35%).1-2
As prison is a potential site of HCV transmission due to injection drug use or tattoos with contaminated paraphernalia, improved prison-specific HCV screening and prevention strategies are needed. 10, 25-26 In one report, while 94% of all inmates are incarcerated in state facilities which have HCV testing polices, 69% of these facilities direct testing to ‘high risk’ groups or per patient request. 27 While testing populations with high rates of injection drug use is efficient for identifying HCV-positive persons, factors contributing to acceptance of testing and completion of treatment also need to be identified.10
Tattoos
Tattoos were a significant independent risk factor for HCV in the total sample and among non-injectors, even after controlling for prison exposure. This finding contributes to the larger body of evidence suggesting tattoos as a potential mode of HCV transmission.19 There is also evidence that tattoos, particularly those received in prison, may be a risk factor given reported sharing of tattoo-making equipment in a population with high HCV infection rates and other risk behaviors for HCV. 28-29
No evidence of sexual risk for HCV
Consistent with previous studies of homeless adults, we found no evidence of HCV risk associated independently with risky sexual behaviors.9 Although HCV was significantly higher in bivariate analysis among clients with two sexual risk behaviors (i.e., more than 15 sexual partners and giving sex for drugs), neither had an independent relationship to HCV infection once other variables were controlled for.
No evidence of intranasal drug use as a risk for HCV
Although HCV was significantly higher in bivariate analysis among clients with a history of intranasal cocaine use, no intranasal drug use variables had an independent relationship to HCV infection after other variables were accounted for.
Severity of Homelessness
As reported elsewhere, 19 we reported marginally higher HCV prevalence among persons who experienced chronic homelessness (i.e., one year or longer cumulatively).
Strengths
Significantly, this study demonstrated the successful collaboration between a community-based interdisciplinary team of HCH clinicians and clinician-researchers with academic researchers. As a function of the project’s organization, clinicians rather than research staff conducted interviews at each site. Other strengths of this study include its multisite design, random patient selection within each site, and extensive information collected from structured interviews, blood tests and medical chart reviews.
Limitations
Most data (other than HCV-antibody status and medical record data) were self-reported and subject to bias (e.g., injection drug use may be underreported due to stigma). Although all eight clinics were in urban settings, and clients were randomly selected within each site, the clinic sites themselves were not randomly selected, limiting generalizability of findings to these specific clinics. However, the demographic characteristics closely parallel figures for a nationally representative sample of homeless adults by Burt on gender, race/ethnicity, and education.30 Finally, interviews were conducted by clinic staff, which may have influenced response rates and the reliability of self-reported data.
Conclusion
There were high concentrations of HCV-antibody positivity among homeless clients overall and in each of the eight HCH primary care clinics studied. Injection drug use was the strongest predictor of HCV-antibody positivity and continues to be the presumptive primary mode of HCV transmission. However, findings suggest that tattoos may also be a significant mode of transmission given that tattoos demonstrated a relationship with HCV that was independent of injection drug use, prison, and other risk factors. Tattoos may particularly help explain HCV among non-injectors. However, given the cross-sectional nature of the study, we were unable to draw causal inferences about the association between HCV and tattoos in this sample.
The high concentrations of HCV-infected adults along with adults engaged in high-risk behaviors make these and similar clinics opportune intervention sites for aggressive and comprehensive services that would include screening, testing, education, and treatment for HCV and other blood-borne diseases, as recommended by the NIH, IOM, CDC and others.1, 5, 23
Our findings support the explicit inclusion of homeless persons in the national agenda on preventing and controlling HCV. The agenda emphasizes that early detection and treatment of infected persons, along with educational efforts for those with high-risk behaviors, are crucial elements for preventing the spread and consequences of HCV. Our study also supports the inclusion of homeless adults in continued epidemiological monitoring and studies of specific modes of transmission. 23 Effective HCV prevention, education and treatment programs for homeless persons could decrease transmission, improve morbidity and mortality rates, and potentially decrease health care costs from end stage liver disease.
Nearly one-third of homeless adults who presented at the eight HCH clinics during the study were already infected with HCV. The majority of these did not know that they had been infected. Many of the rest, although not infected, reported risk behaviors for HCV exposure including injection drug use, non-injection drug use, and having tattoos.
As HCV prevalence was relatively high in all eight homeless clinics sampled, our findings lend weight to earlier studies that identified homeless persons as a high-risk group for HCV infection, primarily due to injection drug use, but also potentially due to non-injection drug use and tattoos. Reducing new cases of HCV in homeless adults requires aggressive risk-behavior screening, testing, and educational interventions to help them protect themselves and others from exposure to HCV. For those already infected with HCV, medical management of the condition is indicated to help mitigate the complications of chronic HCV.5
Increased age and chronic HCV
The median age of homeless adults in the US is increasing over time.32 Chronic health conditions such as hepatitis-related liver cancer and cirrhosis increase with age, and they will present challenges to traditional care giving in an aging homeless population . Researchers warn that public systems of care should expect increasing costs related to HCV infection as homeless and other indigent individuals develop the serious medical sequelae of chronic HCV infection.6, 16
Findings here support the explicit inclusion of homeless persons in the NIH National HCV Agenda which emphasizes early detection and treatment, along with educational efforts, for high-risk and infected persons. 23 Similarly, findings support including homeless adults in voluntary testing to identify new cases of HCV among high-risk persons as recommended by Alter .22
In its 2010 report on the prevention and control of hepatitis B and C, the IOM recommended that federal and state governments reduce the risk of hepatitis C virus infection due to injection drug use by providing comprehensive HCV prevention programs for injectors in community health facilities. Such programs would include education on safer injection practices, access to sterile needle syringes and drug-preparation equipment, and expansion of prevention and care services in settings that injectors and non-injection drug users are likely to use.1, 31
However, the IOM Report concluded that funding for preventive and other viral hepatitis services at community health centers, including homeless programs, had been inadequate.1 IOM authors recommended that public agencies provide adequate resources to federally funded treatment facilities, including primary care sites, to provide comprehensive viral hepatitis services for homeless and other at-risk indigent clients.
Table 2
Table 2
Prevalence of Antibody to Hepatitis C (HCV+) among homeless adult clients of eight HCH clinics by demographic characteristics and potential risk behaviors (N=387).
Acknowledgments
Authors acknowledge the invaluable contribution of lead clinicians and their teams who collected data at the eight HCH study clinics. We further acknowledge the support of Amy Taylor, MD, MHS, Deputy Chief of the Health Care for the Homeless Branch, Division of Programs for Special Populations, Bureau of Primary Health Care, US Health Resources and Services Administration.
Primary funding for this research project was provided by the Homeless Branch, Division of Programs for Special Populations, Bureau of Primary Health Care, of the US Health Resources and Services Administration (HRSA). Additional support for Robertson and Gelberg was provided by the National Institute on Drug Abuse (RO1-DA14294, “Hepatitis B and C Among Homeless Adults.”) Robertson was also supported by the NIAAA National Alcohol Research Center at the Alcohol Research Group of the Public Health Institute in Emeryville, CA. Gelberg was the George F. Kneller Professor of Family Medicine at UCLA.
Contributor Information
Aaron J Strehlow, UCLA School of Nursing 1228 N La Cienega Blvd., #102 West Hollywood, CA 90069-2485 (310) 659-7761 Cell: 213-220-4176 ; astrehlo/at/ucla.edu.
Marjorie J. Robertson, Alcohol Research Group Public Health Institute 8361 Monique Way Cypress, CA 90630 Cell: 510 292 8992 ; robertsonmarjorie/at/yahoo.com.
Suzanne Zerger, Center for Social Innovation 647-435-4616 ; szerger/at/center4si.com.
Catherine Rongey, Gastroenterology and Hepatology San Francisco Veterans Affairs Medical Center University of California, San Francisco Office phone: 1-415-221-4810 ext. 2636 fax: 1-415-750-2196 Cell: 323 286 6024.
Lisa Arangua, 12762 Charmaine Lane Santa Ana Ca 92705 ; larangua/at/mednet.ucla.edu.
Ed Farrell, Medical Director Clinica Family Health Services -- Thornton 8990 N. Washington Street Thornton, CO 80229 720.929.1321 ; efarrell/at/clinica.org.
Adele O’Sullivan, 220 S. 12th Ave. Phoenix, AZ 85007 (602)284-0039 ; aosullivanmd/at/circlethecity.org.
Lillian Gelberg, UCLA David Geffen School of Medicine 10880 Wilshire Blvd, Suite 1800 Los Angeles, CA 90024 310 794 6092 310 794 6097 ; lgelberg/at/mednet.ucla.edu.
1. Institute of Medicine In: Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Colvin H, Mitchell A, editors. The National Academies Press; Washington, D.C.: 2010.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14. [PubMed]
3. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31(4):1014–8. [PubMed]
4. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology. 2002;36(5 Suppl 1):S1–2. [PubMed]
5. Kuehn BM. Silent epidemic of viral hepatitis may lead to boom in serious liver disease. JAMA. 2009;302(18):1949–50. 1954. [PubMed]
6. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–21. 521 e1–6. [PubMed]
7. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31(3):777–82. [PubMed]
8. Ruiz JD, Molitor F, Plagenhoef JA. Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999. AIDS. 2002;16(16):2236–8. [PubMed]
9. Nyamathi AM, Dixon EL, Robbins W, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med. 2002;17(2):134–43. [PMC free article] [PubMed]
10. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(RR-1):1–36. quiz CE1-4. [PubMed]
11. Al Jurdi RK, Burruss JW. Prevalence of hepatitis C in psychiatric institutions. Psychosomatics. 2003;44(5):439–40. [PubMed]
12. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41(1):88–96. [PubMed]
13. Vajdic CM, Grulich AE, Kaldor JM, et al. Specific infections, infection-related behavior, and risk of non-Hodgkin lymphoma in adults. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1102–8. [PubMed]
14. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42(7):513–21. [PubMed]
15. Hall CS, Charlebois ED, Hahn JA, et al. Hepatitis C virus infection in San Francisco’s HIV-infected urban poor. J Gen Intern Med. 2004;19(4):357–65. [PMC free article] [PubMed]
16. Desai RA, Rosenheck RA, Agnello V. Prevalence of Hepatitis C virus infection in a sample of homeless veterans. Soc Psychiatry Psychiatr Epidemiol. 2003;38(7):396–401. [PubMed]
17. Cheung RC, Hanson AK, Maganti K, et al. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol. 2002;34(4):476–80. [PubMed]
18. Schwarz KB, Garrett B, Alter MJ, et al. Seroprevalence of HCV infection in homeless Baltimore families. J Health Care Poor Underserved. 2008;19(2):580–7. [PubMed]
19. Stein JA, Nyamathi A. Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend. 2004;75(1):89–95. [PubMed]
20. Klinkenberg WD, Caslyn RJ, Morse GA, et al. Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Compr Psychiatry. 2003;44(4):293–302. [PubMed]
21. Sherriff LC, Mayon-White RT. A survey of hepatitis C prevalence amongst the homeless community of Oxford. J Public Health Med. 2003;25(4):358–61. [PubMed]
22. Alter MJ. Integrating risk history screening and HCV testing into clinical and public health settings. Am Fam Physician. 2005;72(4):576, 579. [PubMed]
23. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19(3):1–46. [PubMed]
24. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(RR-3):1–13. 15. quiz CE1-4. [PubMed]
25. Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis. 2005;41(2):177–86. [PubMed]
26. Spaulding AC, Weinbaum CM, Lau DT, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144(10):762–9. [PubMed]
27. Beck A, Maruschak L. Hepatitis Testing and Treatment in State Prisons. Bureau of Justic Statistics, Special Report. 2004
28. Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons--not such a pretty picture. Am J Infect Control. 2007;35(7):477–80. [PubMed]
29. Kushel MB, Hahn JA, Evans JL, et al. Revolving doors: imprisonment among the homeless and marginally housed population. Am J Public Health. 2005;95(10):1747–52. [PubMed]
30. Burt M, Aron L, Douglas T, et al. Homelessness: Programs and the People They Serve. 1999.
31. Badiaga S, Raoult D, Brouqui P. Preventing and controlling emerging and reemerging transmissible diseases in the homeless. Emerg Infect Dis. 2008;14(9):1353–9. [PMC free article] [PubMed]
32. Hahn JA, Kushel MB, Bangsberg DR, et al. BRIEF REPORT: the aging of the homeless population: fourteen-year trends in San Francisco. J Gen Intern Med. 2006;21(7):775–8. [PMC free article] [PubMed]